Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

CHRS Coherus BioSciences Inc

Price (delayed)

$0.797

Market cap

$92.4M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.13

Enterprise value

$278.19M

Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients' lives and to deliver significant savings ...

Highlights
Coherus BioSciences's gross margin has surged by 54% YoY
The debt has declined by 44% year-on-year
The gross profit has grown by 34% YoY but it has contracted by 25% from the previous quarter
The equity has plunged by 124% YoY and by 39% from the previous quarter
The net income has plunged by 121% YoY

Key stats

What are the main financial stats of CHRS
Market
Shares outstanding
115.93M
Market cap
$92.4M
Enterprise value
$278.19M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.41
Earnings
Revenue
$197.5M
Gross profit
$111.88M
Operating income
-$114.58M
Net income
-$130.94M
EBIT
-$112.75M
EBITDA
-$106.54M
Free cash flow
$500,000
Per share
EPS
-$1.13
EPS diluted
-$1.09
Free cash flow per share
$0
Book value per share
-$1.58
Revenue per share
$1.7
TBVPS
$2.75
Balance sheet
Total assets
$371.07M
Total liabilities
$554.54M
Debt
$268.2M
Equity
-$183.47M
Working capital
$55.13M
Liquidity
Debt to equity
-1.46
Current ratio
1.22
Quick ratio
0.57
Net debt/EBITDA
-1.74
Margins
EBITDA margin
-53.9%
Gross margin
56.6%
Net margin
-66.3%
Operating margin
-58%
Efficiency
Return on assets
-26.2%
Return on equity
N/A
Return on invested capital
-41.2%
Return on capital employed
-97.2%
Return on sales
-57.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CHRS stock price

How has the Coherus BioSciences stock price performed over time
Intraday
1.92%
1 week
-0.26%
1 month
-27.55%
1 year
-55.22%
YTD
-42.25%
QTD
-1.24%

Financial performance

How have Coherus BioSciences's revenue and profit performed over time
Revenue
$197.5M
Gross profit
$111.88M
Operating income
-$114.58M
Net income
-$130.94M
Gross margin
56.6%
Net margin
-66.3%
The net margin has dropped by 154% year-on-year
The net income has plunged by 121% YoY
Coherus BioSciences's gross margin has surged by 54% YoY
The operating income has grown by 44% YoY but it has contracted by 2.6% from the previous quarter

Price vs fundamentals

How does CHRS's price correlate with its fundamentals

Growth

What is Coherus BioSciences's growth rate over time

Valuation

What is Coherus BioSciences stock price valuation
P/E
N/A
P/B
N/A
P/S
0.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.41
Coherus BioSciences's EPS has shrunk by 55% YoY
The equity has plunged by 124% YoY and by 39% from the previous quarter
The P/S is 79% below the 5-year quarterly average of 2.2 and 22% below the last 4 quarters average of 0.6
The revenue has declined by 26% since the previous quarter and by 13% year-on-year

Efficiency

How efficient is Coherus BioSciences business performance
The return on assets has dropped by 170% year-on-year

Dividends

What is CHRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CHRS.

Financial health

How did Coherus BioSciences financials performed over time
The total assets is 33% less than the total liabilities
The total assets has plunged by 51% YoY and by 17% from the previous quarter
Coherus BioSciences's quick ratio has decreased by 44% YoY and by 35% QoQ
The equity has plunged by 124% YoY and by 39% from the previous quarter
The debt to equity has soared by 75% YoY and by 28% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.